The influence of radiation modality and lymph node dissection on survival in early-stage endometrial cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 5, 2012, Pages 1872-1879

  Chino, Junzo P ^a   Jones, Ellen ^b   Berchuck, Andrew ^a   Secord, Angeles Alvarez ^a   Havrilesky, Laura J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Lymphadenectomy; SEER analyses; Uterine cancer

Indexed keywords

ADJUVANT RADIATION; BRACHYTHERAPY; DATA SETS; ENDOMETRIAL CANCER; INTERNATIONAL FEDERATION; LYMPH NODE; LYMPHADENECTOMY; OVERALL SURVIVAL; POSTOPERATIVE RADIATION THERAPY; SEER ANALYSES; UTERINE CANCER; VAGINAL BRACHYTHERAPY;

BODY FLUIDS; DISEASES; DISSECTION; ONCOLOGY;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL;

AGED; BRACHYTHERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RISK; SEER PROGRAM; SURVIVAL ANALYSIS;

EID: 84858706470     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.03.054     Document Type: Article

References (30)

1. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol Oncol 2004;92: 744-751. (Pubitemid 38251372)
2. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): An open-label, non-inferiority, randomised trial. Lancet 2010; 375:816-823.
3. Scholten AN, van Putten WL, Beerman H, et al. Postoperative radiotherapy for Stage 1 endometrial carcinoma: Long-term outcome of the randomized PORTEC trial with central pathology review. Int J Radiat Oncol Biol Phys 2005;63:834-838. (Pubitemid 41400072)
4. Blake P, Swart AM, Orton J, et al. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): Pooled trial results, systematic review, and meta-analysis. Lancet 2009; 373:137-146.
5. Aalders J, Abeler V, Kolstad P, et al. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histopathologic study of 540 patients. Obstet Gynecol 1980;56:419-427. (Pubitemid 10018299)
6. Morrow CP, Bundy BN, Homesley HD, et al. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: A Gynecologic Oncology Group Study. Gynecol Oncol 1990;36:166-171. (Pubitemid 20061279)
7. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008;108:226-233. (Pubitemid 350299451)
8. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: Results of a randomised trial. Br J Cancer 2006;95:266-271. (Pubitemid 44187586)
9. Brady LW, Lewis GC Jr., Antoniades J, et al. Evolution of radiotherapeutic techniques. Gynecol Oncol 1974;2:314-323.
10. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: First results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547-3556.
11. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial. J Natl Cancer Inst 2008;100:1707-1716.
12. Kitchener H, Swart AM, Qian Q, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): A randomised study. Lancet 2009;373:125-136.
13. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) Uterine Cancer. 2010.
14. Lee CM, Szabo A, Shrieve DC, et al. Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma. JAMA 2006;295:389-397. (Pubitemid 43144975)
15. National Cancer Institute. Surveillance epidemiology and end results. Bethesda, MD. 2010.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
18. Cox D. Regression models and life tables. J Royal Stat Soc Series B 1972;34:187-220.
19. Fisher RA. On the interpretation of x(2) from contingency tables, and the calculation of P. J Royal Stat Soc 1922;85: 87-94.
20. Feinstein AR, Sosin DM,Wells CK. TheWill Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604-1608. (Pubitemid 15062653)
21. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-2041. (Pubitemid 17145924)
22. Trimble EL,Kosary C, Park RC. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998;71:340-343. (Pubitemid 29022315)
23. Cragun JM, Havrilesky LJ, Calingaert B, et al. Retrospective analysis of selective lymphadenectomy in apparent earlystage endometrial cancer. J Clin Oncol 2005;23:3668-3675.
24. Parthasarathy A, Kapp DS, Cheung MK, et al. Adjuvant radiotherapy in incompletely staged IC and II endometrioid uterine cancer. Obstet Gynecol 2007;110:1237-1243. (Pubitemid 351326064)
25. Lutman CV, Havrilesky LJ, Cragun JM, et al. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology. Gynecol Oncol 2006;102:92-97. (Pubitemid 43870232)
26. Signorelli M, Guerra L, Buda A, et al. Role of the integrated FDG PET/CT in the surgical management of patients with high risk clinical early stage endometrial cancer: Detection of pelvic nodal metastases. Gynecol Oncol 2009;115:231-235.
27. Pandit-Taskar N, Gemignani ML, Lyall A, et al. Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecol Oncol 2010;117:59-64.
28. Khoury-Collado F, Glaser GE, Zivanovic O, et al. Improving sentinel lymph node detection rates in endometrial cancer: How many cases are needed? Gynecol Oncol 2009;115: 453-455.
29. Levan K, Partheen K, Osterberg L, et al. Identification of a gene expression signature for survival prediction in type I endometrial carcinoma. Gene Expr 2010;14:361-370.
30. Ratner E, Tuck D, Richter C, et al. MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 2010;118:251-257.